Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | ESRRG | P62508 | 12/20 | 0.61 |
| ▸ | ESRRB | O95718 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20902780 | 0.91 | CA1 (0.71) | CA1CA2ESRRGESRRBKMT2A | |
| SCHEMBL3244363 | 0.85 | CA1 (0.64) | CA1CA2ESRRGESRRBLMNA | |
| SCHEMBL3240039 | 0.85 | GAA (0.67) | CA1CA2ESRRGLMNABCHE | |
| SCHEMBL5176818 | 0.83 | CA1 (0.62) | CA1CA2ESRRGTMEM97MEN1 | |
| SCHEMBL4575081 | 0.83 | MTOR (0.56) | CA1CA2BCHETMEM97SIGMAR1 | |
| SCHEMBL4027988 | 0.83 | CA1 (0.62) | CA1CA2ESRRGESRRBLMNA | |
| SCHEMBL3244925 | 0.83 | CA1 (0.62) | CA1CA2ESRRGLMNABCHE | |
| SCHEMBL3273909 | 0.83 | L3MBTL1 (0.68) | CA1CA2LMNAMEN1KMT2A | |
| SCHEMBL5177175 | 0.83 | CA1 (0.52) | CA1CA2ESRRGESRRBBCHE | |
| Hydrochloric Acid SCHEMBL4026088 | 0.82 | L3MBTL1 (0.66) | CA1CA2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | CA1 4644/4885CA2 4559/4885ESRRG 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.